AMG 193

DRUG3 trials

Sponsors

Amgen Inc.

Conditions

Advanced MTAP-null solid tumorsIn Part 1Non-Small Cell Lung Cancerin Part 2subjects with advanced MTAP-null Non Small-Cell Lung Cancersubjects with advanced MTAP-null solid tumors and

Phase 1

A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors

CompletedCTIS2023-504364-42-00

Amgen Inc.In Part 1, in Part 2, subjects with advanced MTAP-null Non Small-Cell Lung Cancer +1

Start: 2024-09-12End: 2025-04-28Target: 12Updated: 2024-07-10

A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors

RecruitingCTIS2023-504363-17-00

Amgen Inc.Advanced MTAP-null solid tumors

Start: 2022-05-13Target: 98Updated: 2026-01-07

Phase 2

A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects with Methylthioadenosine Phosphorylase (MTAP)-deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)

RecruitingCTIS2024-514459-14-00

Amgen Inc.Non-Small Cell Lung Cancer

Start: 2025-04-22Target: 107Updated: 2025-11-06